Alison A. Haggerty

  • Partner
  • 1271 Avenue of the Americas
  • New York, NY 10020
  • USA
  • T +1.212.906.1320


Ali Haggerty advises issuers and investment banking firms in capital markets transactions, with a focus on initial public offerings, follow-on equity offerings, and convertible debt offerings in growth industries.

Ms. Haggerty serves a mix of companies and financial institutions in connection with complex equity and debt securities offerings. She brings particular experience handling capital markets transactions on behalf of all of the major US investment banks and leading innovators in technology and the life sciences.

Ms. Haggerty also regularly counsels publicly traded companies on general corporate and securities law matters, including governance issues, reporting obligations, and stock exchange rules and requirements. 


Ms. Haggerty’s representative experience includes advising the issuer or underwriters in connection with securities offerings for the following companies:

  • ADC Therapeutics
  • Aquantia
  • Axovant
  • Cara Therapeutics
  • Catabasis
  • Datadog
  • Duolingo
  • Etsy
  • European Wax Center
  • Everyday Health
  • FIGS
  • Fluence Energy
  • Imara
  • Immunovant
  • MongoDB
  • Monte Rosa
  • Myovant Sciences
  • Ovid
  • Prevail Therapeutics
  • Progyny
  • RenalytixAI
  • Rivian
  • Schrodinger
  • Strongbridge Biopharma
  • WAVE Life Sciences
  • Zentalis Pharmaceuticals

*Certain matters above were handled prior to joining Latham

“She is a rising star in equity capital markets.”Chambers USA 2021
Bar Qualification
  • New York
  • JD, New York University School of Law, 2010
    cum laude
  • BS, University of North Carolina, Chapel Hill, 2004
  • Healthcare & Life Sciences
  • Technology
  • Capital Markets
  • Public Company Representation